

# Clinical development of a novel synthetic AHR agonist PB542 as an IBD therapeutics

Parenchyma Biotech



IMMUNOLOGY	Non-Clinical
Product Type	Synthetic small molecule
Indication	Inflammatory bowel disease
Target	Aryl hydrocarbon receptor
MoA(Mechanism of Action)	PB542 is a potent, synthetic AHR agonist that suppresses pathogenic Th17 responses, while promoting Treg activities, in IBD.
Competitiveness	PB542 has proved to be superior to natural AHR agonists or IBD drugs in its therapeutic efficacy on advanced IBD in pre-clinical settings: PB542 lowers pathogenic Th17 responses in advanced IBD, which is linked to a marked increase in intestinal Treg expansion; It normalizes the barrier function of inflamed intestinal epithelial cells and prevent their progression into colon cancer after exposure to carcinogen.
Development Stage	Non-Clinical
Route of Administration	Oral